Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated to v3.4.2, replacing the previous v3.4.1.SummaryDifference0.0%

- Check21 days agoChange DetectedThe change is limited to a revision number update from v3.4.0 to v3.4.1; no study content or functionality appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check29 days agoChange DetectedThe page adds a visible glossary and updates QC-related labels (e.g., Last Update Submitted that Met QC Criteria) with Revision: v3.4.0, while older QC wording and the No FEAR Act data phrasing were removed.SummaryDifference0.2%

- Check43 days agoChange DetectedRevision: v3.3.4 is now displayed on the page, replacing the previous v3.3.3.SummaryDifference0.1%

- Check72 days agoChange DetectedA new Locations section has been added and California is now listed under locations, replacing the previous California Locations grouping. The HHS Vulnerability Disclosure footer link has been removed and the page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.